The Robert A. Winn Excellence in Clinical Trials Award Program announced 79 new physician-researchers from across the U.S. have been selected to join the fifth annual cohort of the Winn Career Development Award program, a rigorous two-year curriculum designed to advance community-focused clinical research.
Limited access to digital resources may be one reason why rural cancer survivors are underrepresented in cancer research, according to researchers at the University of Arkansas for Medical Sciences Institute for Community Health Innovation.
Xilio Therapeutics announced data from its ongoing Phase II clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq) in patients with microsatellite stable metastatic colorectal cancer.
The Alliance for Clinical Trials in Oncology has launched a new clinical trial seeking to evaluate the feasibility of delivering a structured exercise program entirely through telehealth for patients with cancer receiving chemotherapy with the ultimate goal of reducing fatigue and disability.
A new type of cancer cell that “warrants urgent investigation” has been discovered in childhood leukaemia, and could impact clinical care. Research into new or repurposed treatments that target this new cell type could give hope to children and families worldwide.
FDA has granted full approval of Komzifti (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Komzifti is the first and only once-daily, oral menin inhibitor approved for R/R NPM1-mutated AML, a devastating blood cancer with limited treatment options.
Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, a biotechnology company developing next-generation T cell receptor-based therapies in oncology, announced that they have entered into a collaboration and license agreement to advance a novel in vivo approach to cell therapy for the treatment of solid tumors.
George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
To say that it has been an eventful few months for George Tidmarsh would be a bit of an understatement.
Research1 has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway.
